(15 days)
Not Found
No
The summary describes a passive blood storage reservoir with a biocompatible coating. There is no mention of any computational or analytical functions that would suggest the use of AI/ML.
No
The device is a storage reservoir for blood used in an extracorporeal bypass circuit. While it is part of a medical procedure, its function is primarily for storage and compatibility, not direct therapeutic intervention on a patient's condition or disease state.
No
The device is a storage reservoir for blood during extracorporeal bypass surgery, not a tool for diagnosing medical conditions.
No
The device description clearly states it is a "soft, flexible polyviny chloride plastic bag" and describes physical characteristics and coatings, indicating it is a hardware device.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "as a storage reservoir for blood in an extracorporeal bypass circuit". This describes a device used during a medical procedure on a patient, not a device used to test samples outside the body to diagnose a condition.
- Device Description: The description details a "soft, flexible polyviny chloride plastic bag designed for use during extracorporeal bypass surgery". This aligns with the intended use and not with the typical components of an IVD.
- Lack of IVD Characteristics: The text does not mention any of the key characteristics of an IVD, such as:
- Analyzing samples (blood, urine, tissue, etc.)
- Detecting specific analytes (proteins, DNA, chemicals, etc.)
- Providing diagnostic information about a patient's health status
The device is clearly intended for use in a surgical setting as part of an extracorporeal circuit, which is not the function of an IVD.
N/A
Intended Use / Indications for Use
The MVR 1200 PC is a sterile, nonpyrogenic device intended for use as a storage reservoir for blood in an extracorporeal bypass circuit. The MVR 1200 PC must not be used for longer than 6 hours.
Product codes (comma separated list FDA assigned to the subject device)
DTN
Device Description
Sorin Monolyth Venous Reservoir 1200 PC with Phosphorilcholine coating (hereafter referred to as the MVR 1200 PC) is a soft, flexible polyviny chloride plastic bag designed for use during extracorporeal bypass surgery as in-line venous bag reservoir. Blood contact surfaces of the MVR 1200 PC have been coated with phosphorylcholine (PC) coating improves blood compatibility, resulting in reduced platelet adhesion on the coated surfaces.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
BIOCOMPATIBILITY TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-11995 and / Complete Battlery of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the MVR 1200 PC (accelerated aging). The device aged up to three years was tested for Hemolysis, Cytotoxicity, Irritation, Acute Systemic Toxicity, Sterility, Pyrogenicity, ETO residuals and package integrity testing were also conducted. The results of the testing met established specifications.
IN VITRO TEST RESULTS:
In vitro testing were carried out in accordance with the requirements of "Guidance for Blood Extracorporeal m firs to the barner 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, Diood Onean Beloamor Cro(in Cardiovascular Implants and Artificial Organs – Extra Corporeal Blood-Gas Exchangers (Oxygenator)" when applicable for providing the data necessary to demonstrate both the substantial equivalence with the predicate device and also compliant with safety and effectiveness requirements. The device was aged up to 3 years and was tested for minimum operating blood volume, requirements, burstileak testing, fill capacity, in vitro hemolysis/cell depletion, air removal efficiency and uniformity test of the PC coating. The results of these tests met established specifications. For comparative unfinoning test of the F & outing. The been conducted also on the MVR 1200 predicate device. purposes, the Same tocking, mier appance data previously submitted in the Synthesis 510(k) (K022450) for This of of the characterization and in the Synthesis Mimesys 510(k) (K031223) for flaking and leaching studies in order to evaluate the stability of the coating.
The results of the study showed that the device characteristics between MVR 1200 PC and MVR 1200 were comparable.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
0
DEC 1 1 2003
K033714
p1/2
| 510(k) SUMMARY | |
|---|---|
| SUBMITTER: | Dideco S.p.A. |
| 86, Via Statale 12 Nord | |
| 41037 Mirandola (MO) Italy | |
| CONTACT PERSON: | Luigi Vecchi |
| Phone: 011 39 0535 29811 | |
| Fax: 011 39 0535 25229 | |
| DATE PREPARED: | November 26, 2003 |
| DEVICE TRADE NAME: | MVR 1200 PC: Sorin Monolyth Venous Reservoir 1200 PC |
| with phosphorylcholine coating (hereinafter called PC | |
| coating) | |
| COMMON NAME: | Softshell Venous Reservoir |
| CLASSIFICATION NAME: | Reservoir, Blood Cardiopulmonary Bypass |
| PREDICATE DEVICES: | MVR 1200 Sorin Monolyth Venous Reservoir (K933481). |
| SYNTHESIS Adult Membrane Oxygenator with Integrated | |
| Arterial Filter and Hardshell Venous/Cardiotomy Reservoir | |
| Mimesys treated (Phosphorilcholine coating hereinafter | |
| called PC coating) (K022450), | |
| SYNTHESIS MIMESYS Adult Membrane Oxygenator with | |
| Integrated Arterial Filter and Hardshell venous/Cardiotomy | |
| Reservoir Mimesys Treated (PC coating) including the CVR | |
| 1200 PC with PC coating soft shell reservoir (K031223). |
DEVICE DESCRIPTION:
Sorin Monolyth Venous Reservoir 1200 PC with Phosphorilcholine coating (hereafter referred to as the MVR 1200 PC) is a soft, flexible polyviny chloride plastic bag designed for use during extracorporeal bypass surgery as in-line venous bag reservoir. Blood contact surfaces of the MVR 1200 PC have been coated with phosphorylcholine (PC) coating improves blood compatibility, resulting in reduced platelet adhesion on the coated surfaces.
INDICATION FOR USE:
The MVR 1200 PC is a sterile, nonpyrogenic device intended for use as a storage reservoir for blood in an extracorporeal bypass circuit. The MVR 1200 PC must not be used for longer than 6 hours.
TECHNOLOGICAL CHARACTERISTICS:
The MVR 1200 PC is essentially identical to the MVR 1200 predicate device with respect to operating principles, control mechanisms and materials. The only modification made to the MVR 1200 PC is the extension of the coating material that bears the claim of reduced platelet adhesion on treated surfaces, to all blood contact surfaces of the softshell venous reservoir. The MVR 1200 PC shares the identical coating material, bicompatibility and manufacturing process of the PC coating with the Synthesis and the CVR 1200 PC coated (included in the Synthesis Mimesys) predicate devices.
The softshell venous reservoir is ethylene oxide sterilized and has a nonpyrogenic fluid path. It is for single use only. The device is not intended to be used for periods greater than 6 hours.
1
1 2/2
BIOCOMPATIBILITY TEST RESULTS:
A complete battery of tests were carried out in accordance with the requirements of ISO 10993-11995 and / Complete Battlery of the ISO 10993 standard for biocompatibility testing on the raw materials. Testing was performed on the MVR 1200 PC (accelerated aging). The device aged up to three years was tested for Hemolysis, Cytotoxicity, Irritation, Acute Systemic Toxicity, Sterility, Pyrogenicity, ETO residuals and package integrity testing were also conducted. The results of the testing met established specifications.
IN VITRO TEST RESULTS:
In vitro testing were carried out in accordance with the requirements of "Guidance for Blood Extracorporeal m firs to the barner 510(k) Submission" Final Guidance for Industry and FDA issued on November 29, Diood Onean Beloamor Cro(in Cardiovascular Implants and Artificial Organs – Extra Corporeal Blood-Gas Exchangers (Oxygenator)" when applicable for providing the data necessary to demonstrate both the substantial equivalence with the predicate device and also compliant with safety and effectiveness requirements. The device was aged up to 3 years and was tested for minimum operating blood volume, requirements, burstileak testing, fill capacity, in vitro hemolysis/cell depletion, air removal efficiency and uniformity test of the PC coating. The results of these tests met established specifications. For comparative unfinoning test of the F & outing. The been conducted also on the MVR 1200 predicate device. purposes, the Same tocking, mier appance data previously submitted in the Synthesis 510(k) (K022450) for This of of the characterization and in the Synthesis Mimesys 510(k) (K031223) for flaking and leaching studies in order to evaluate the stability of the coating.
The results of the study showed that the device characteristics between MVR 1200 PC and MVR 1200 were comparable.
CONCLUSIONS:
The results of in vitro studies demonstrate that the MVR 1200 PC device performs in a manner substantially r rie results of in 7 are clause demonstrate that the phosphorylcholine coating is biocompatible and functional tests demonstrate that its performance are equivalent to the MVR 1200 blocompanible and functional tools and its intended use. Additional testing has demonstrated the effectiveness of production techniques to assure that the soft shell venous reservoir is sterile and non-pyrogenic.
2
Image /page/2/Picture/11 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 1 1 2003
Dideco S.P.A. c/o Mr. Barry Sall Parexel International Corp. 195 West Street Waltham, MA 02451-1163
Re: K033714
MVR 1200 PC Sorin Monolyth Venous Reservoir 1200 PC with PohosphoryIcholine Coating Regulation Number: 21 CFR 870.4400 Regulation Name: Cardiopulmonary Bypass Blood Reservoir Regulatory Class: Class II (two) Product Code: DTN Dated: November 26, 2003 Received: November 26, 2003
Dear Mr. Sall:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your de for to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Barry Sall
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address.
Sincerely yours,
Clas. Mllio
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known): K033714
MVR 1200 PC Sorin Monolyth Venous Reservoir 1200 PC with Device Name: pohosphoryicholine coating
Indications For Use:
The MVR 1200 PC is intended for use as a storage reservoir for blood in an extracorporeal bypass circuit for periods up to six hours.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use V (Per 21 CFR 801.109)
OR
Over-The-Counter Use_
O. Malla
Division ( cular Devices
510(k) Number
(Optional format 1-2-96)